Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.
Alveolar macrophages are immune cells that live in the tiny air sacs of the lungs. Under normal conditions, these cells act as guardians, keeping the lungs healthy, supporting breathing, and ...
A human cell culture model of the lung's most important immune cells, alveolar macrophages, helped make a key finding that is prompting researchers to rethink the role of another immune protein. A ...
A human cell culture model of the lung's most important immune cells, alveolar macrophages, helped make a key finding that is prompting researchers to rethink the role of another immune protein in ...
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, ...
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide and is characterized by an abnormal inflammatory reaction of the lungs to inhaled particles, such as ...
Though the COVID-19 pandemic provided a brief respite, influenza virus is back in circulation and, as usual, poses a special danger to people over the age of 65. But why are older people more ...
Though the COVID-19 pandemic provided a brief respite, influenza virus is back in circulation and, as usual, poses a special danger to people over the age of 65. But why are older people more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results